FinancialNewsMedia.com News Commentary
PALM BEACH, Fla., Dec. 21, 2022 /PRNewswire/ -- The global cannabis cultivation market has grown significantly during the COVID-19 pandemic. The demand for hemp is rapidly growing, as many developed countries have legalized the cultivation and processing of hemp after recognizing the levels of CBD present in it, which is leading to an increased demand for hemp extracts for various applications in several sectors, including pharmaceuticals, cosmetics, nutraceuticals, and food & beverage. Hemp is regarded as an agricultural commodity produced in over 40 countries. A report from Grand View Research projected that the global cannabis cultivation market size, which was valued at USD 323.9 billion in 2021 is expected to expand at a compound annual growth rate (CAGR) of 21.4% from 2022 to 2030. The report said: "Growing legalization and the adoption of cannabis for the treatment of chronic diseases are the key factors driving the growth of the market. In addition, the liberalization of laws related to cannabis cultivation, especially for hemp cultivation by various countries due to low THC content is further increasing its adoption. Furthermore, the legalization of marijuana in various geographies and its increasing adoption for medical purposes are factors driving the market for cannabis cultivation… And that figure is certain to climb as more individuals come around to the concept of legalizing marijuana across the U.S." Active Cannabis stocks in news today include:
CannaPharmaRx, Inc. (OTCPK: CPMD),
Trulieve Cannabis Corp. (OTCQX: TCNNF) (CSE: TRUL),
Curaleaf Holdings, Inc. (OTCQX: CURLF) (CSE: CURA),
Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY),
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB).
"Based on biomass, the hemp segment dominated the market for cannabis cultivation and accounted for a revenue share of around 80% in 2021. The high share is attributable to the increasing adoption of hemp and derived products and its growing acceptance among users due to its low THC content. Furthermore, marijuana is expected to be the fastest-growing segment, growing at a significant growth rate over the forecast period. This growth can be attributed to the growing legalization of marijuana in various countries for medical and adult use. In addition, promising government reforms regarding the utilization of hemp in many countries are increasing the adoption of hemp and hemp-derived products. It added: "In 2021, based on application, industrial consumption accounted for the highest revenue share of 73.3% in the cannabis cultivation market. This is owing to the growing application of marijuana and hemp in various industries such as pharmaceuticals, personal care and cosmetics, nutraceuticals, and food and beverages. Furthermore, factors such as the growing usage of cannabis and its derivatives as raw material by companies to produce innovative cannabis-infused products are expected to propel the growth of the market for cannabis cultivation during the forecast period."
CannaPharmaRx, Inc. (OTC PINK:CPMD)
BREAKING NEWS -
CannaPharmaRx Receives Cultivation License from Health Canada and Projects 2023 Annual Revenue over $30 Million - CannaPharmaRx, Inc., a future leader in ultramodern, highly efficient cannabis production facilities announced today it received its cultivation license from Health Canada.
The license, LIC-3JCQW6DIU0 is a major step towards production. A standard cultivation license is necessary for larger companies that want to build and grow in a large-scale facility. Upon receiving the cultivation license the company can now grow cannabis and sell wholesale to other licensed producers.
Now that the cultivation license is approved the company anticipates completing the first harvest and sales during Q1 2023 with estimated annual revenue over $30 million.
"The company now has the facility in Cremona in the final preparations of facility opening. As a result of a multi-million dollar offtake agreement, several strains of genetics for a variety of high-quality cannabis products and a cultivation license, we are primed to enter the cannabis market. This keeps us on track to complete our first harvest and distribution during the next few months with rapid revenue expansion," stated Nick Colvin, CEO of CannaPharmaRx.
Read this entire press release and more news for CannaPharmaRx at:
In other cannabis industry news of note includes:
Trulieve Cannabis Corp. (OTCQX: TCNNF)
(CSE: TRUL), a leading and top-performing cannabis company in the United States, recently announced their partnership with California-based Connected Cannabis and AlienLabs. As part of the announcement, Trulieve is the exclusive provider of Connected Branded products throughout Florida.
"Trulieve consistently seeks ways to introduce new products and better serve our patients," said Kim Rivers, CEO of Trulieve. "Connected and AlienLabs represent a portfolio of top-shelf strains that have benefited medical patients in other states, and we're now excited to exclusively offer these products exclusively in Florida."
Curaleaf Holdings, Inc. (OTCQX: CURLF)
(CSE: CURA), a leading international provider of consumer cannabis products, recently announced that its third "The Farmer's Select" product collaboration is now available across California in partnership with Autumn Brands, a woman-and-family-owned farm nestled on the coast of Santa Barbara County.
Autumn Brands cannabis is grown using sustainable farming techniques, natural sunlight and 100% no-spray cultivation. Utilizing a closed-loop watering system, Autumn Brands ensures that no water is wasted during the growing process and all organic waste is composted. This focus on quality, consistency and sustainability ensures nothing but the best cannabis reaches consumers.
Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, recently announced that the Company will release financial results for its second quarter ended November 30, 2022 on January 9, 2023.
Live Audio Webcast - Tilray will host a live audio webcast to discuss these results at 8:30 am Eastern Time, which can be accessed on the Investors section of Tilray's website at . A replay will be available and archived on the Company's website. Additionally, the live audio webcast will be syndicated on the investor app.
Retail Investor Q&A - Tilray Brands stockholders can submit and upvote questions to Tilray via the stockholder Q&A platform Say Technologies beginning today and until January 8, 2023. To submit questions ahead of the webcast, please visit the Say Technologies platform at .
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, recently announced its Greybeard Cannabis Co. brand has won KIND Magazine's 'Best Diamonds of the Year' award, as voted by hundreds of budtenders, store managers and independent cannabis retail owners across Canada.
Greybeard is known for its premium cannabis flower, vapes and concentrates including Trufflez Diamonds & Sauce and FPOG Live Resin Diamonds & Sauce. The Greybeard brand joined Aurora's portfolio when the company acquired Thrive Cannabis earlier this year.
"We're proud to be recognized by some of the most important and influential members of the cannabis industry - retailers and budtenders," says Geoff Hoover, Senior Vice President of Consumer at Aurora Cannabis. "This award is a testament to our continued commitment to quality and our team's unwavering focus and passion for delivering only the best products for our consumers."
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty six hundred dollars for news coverage of the current press releases issued by CannaPharmaRx, Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact email: [email protected] - +1(561)325-8757
Longtime Customers Turn Passion for Brand into New Business Venture with Plans to Open Gym in Minnesota
DALLAS, Dec. 20, 2022 /PRNewswire/ -- The Little Gym International, the world's premier enrichment and physical development center for children ages four months through 12 and part of the youth enrichment growth-focused platform Unleashed Brands, has recently signed a new franchise agreement with longtime customers Jenny and Brandon Conard, who brought their daughters to The Little Gym across the world for years and are now set to open a gym in Maple Grove, Minnesota early next year.
After graduating college, Jenny received her degree in Adaptive Physical Education and went on to teach for over eight years. During this time, she and her husband Brandon had two daughters and juggled numerous moves due to Brandon's career. However, no matter where they moved, The Little Gym always remained a consistent place to take their kids for activity, socialization and physical development for six straight years, starting at age three. This was even the case when the family moved overseas to Kuwait for three years and luckily found a location nearby.
"Since we've taken our girls to The Little Gym all of their lives, we've discovered the value of early development at a young age," said Jenny Conard. "What makes The Little Gym such a special place is the three-dimensional learning program that is incorporated into the children's lives. We're thrilled to have witnessed our girl's progression at the gym and it truly is an honor for us to bring a location to the community of Maple Grove."
The Little Gym teaches kids social and physical skills appropriate to each stage of childhood by creating opportunities to experience achievement and build self-confidence. At the core of the international franchise's mission is becoming the foundation of a child's development that will set them up for success. Through three-dimensional learning including physical activities, cognitive skills and social and emotional learning, the core teaching methods create opportunities for children to experience achievement and build self-confidence.
For more information on bringing a The Little Gym to a community near you, visit .
About The Little Gym International
The Little Gym International is an internationally recognized program that helps children build the developmental skills and confidence needed at each stage of childhood. The very first location was established in 1976 by Robin Wes, an innovative educator with a genuine love for children. The Little Gym International, Inc., headquartered in Scottsdale, Ariz., was formed in 1992 to franchise The Little Gym concept. Today, The Little Gym International has nearly 400 locations in over 31 countries including the U.S., Canada, China, the United Kingdom, Thailand and more. For more information, visit The Little Gym at .
About Unleashed Brands
Unleashed Brands, currently includes portfolio brands Urban Air, Snapology, The Little Gym, XP League, Class 101 and Premier Martial Arts and was founded to curate and grow a portfolio of the most innovative and profitable brands that help kids learn, play and grow. Over the last 10 years, the team at Unleashed Brands has built a proven platform and know-how for scaling businesses focused on serving families. Its mission is to impact the lives of every kid by providing fun, engaging and inspiring experiences that help them become who they are destined to be. For more information, please visit .
SOURCE The Little Gym International, Inc.
TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a business update and details of its current commercialization strategy. MVMD is an early-stage biotech business which, since inception, has focused its resources on investing in multiple research and development (“R&D”) initiatives. The Company is pleased to confirm that it has shifted focus to the commercialization strategy for those of its projects and technologies that it believes will best provide viable revenue streams for long-term company health and shareholder value. There are three primary lines of business MVMD is currently working towards commercial advancement in: (1) novel innovations that improve the administration and efficacy of nutraceutical health and wellness products; (2) agricultural plant signaling technology that organically drives increases in crop yields and supports the reduction of fertilizer usage; and (3) the application of solubilized drugs to positively impact husbandry animal health. “This is a significant milestone for MVMD as we transition from an R&D-focused biotech start-up business into a commercially focused biotech entity with revenue-generating activities,” stated Dennis Hancock, President & CEO of MVMD. “We believe we have identified a great pathway to generate positive cashflow as early as the 2023 calendar year that will support our goal to create shareholder value. I believe this next phase of growth for MVMD will be an exciting validation of our progress.” In support of its commercialization efforts, MVMD holds a license from Agrarius Corp. for the rights to distribute its Agrarius plant signaling technology, and currently has two wholly owned technologies; a) patented Quicksome™ molecule formulation and delivery technology, and b) patented Quicksol™ solubility formulation and delivery technology. LINE OF BUSINESS UPDATES: Nutraceuticals As previously disclosed, following evaluations of North American GMP manufacturing options for MVMD’s nutraceutical product strategy, the Company entered into a license agreement with its selected third-party lead production partner in the United States. The Company strategically secured its lead manufacturing partner as a licensee, who will in turn produce nutraceutical products based on, or embodying, MVMD’s proprietary technologies for third parties, who will then be approved by MVMD and who will have an agreement with Company. The Company believes this strategy will help to ensure product quality, support the ability to scale production, streamline the audit process for royalty agreements, and provide the necessary protection of its technology and trade secrets, versus having numerous licensed partners, each replicating the manufacturing process for their own products. Securing the lead manufacturer and finalizing the scaled GMP production environment aligns with MVMD’s anticipated increased business development efforts and the Company’s plans to secure additional nutraceutical licensing partnerships for production in the 2023 calendar year. This timeline has been updated from the anticipated late 2022 date due to the licensed third-party lead production partner’s current process to establish a scaled GMP production line capable of larger volume outputs, including the installation of equipment to support the required manufacturing process that embeds MVMD’s Quicksome™ formulation approach. MVMD’s production partner has been working to support the Company’s license agreement with Circadian Wellness Corp. (“Circadian”) by way of finalizing the proprietary formulations for mushroom-infused products Circadian intends to market under its Eons brand. Circadian’s license from MVMD supports the desire to achieve an increase in overall molecule efficacy with the Company’s Quicksome™ technology applied across a variety of rapid dissolve sublingual and dermal products in the functional mushroom space. The initial product formulation work and dissolution testing has been positive in MVMD’s view. In early November, Circadian launched its initial products in the nutraceutical space for the United States market: a mushroom infused “smart coffee” and a chewable gummy product designed to aid in sleep. The focus in the next product phase for the Eons brand is mushroom-infused sublingual sleep and energy products and a pain management cream that embodies MVMD’s technology. Although outside of MVMD’s control, it is anticipated that Circadian will be introducing consumer products that embody MVMD’s technology under its Eons brand for sale in the United States in the first half of the 2023 calendar year. Agriculture In September 2022, the Company announced the initiation of commercial sales activity and related business development investments to support in-field trialing of Agrarius, a certified organic product owned by Agrarius Corp. (“AC”). AC isa private US corporation in which the Company holds an equity interest and from which it has licensed certain rights regarding the distribution of AC’s product, Agrarius . The Agrarius product is delivered in a liquid concentrate form that gets mixed with water at the point of application and then applied via sprayer to agricultural crop plants ideally twice during a plant’s lifecycle. Agrarius has been tested across numerous major agricultural crops and has demonstrated its ability to naturally increase crop yields from approximately ten to fifty percent or more depending on crop type, reduce fertilizer usage by more than thirty percent, and increase general resilience to pests and climate change forces such as drought. “We believe Agrarius presents a significant opportunity to support MVMD’s growth objectives given the rapidly changing global agricultural landscape,” continued Mr. Hancock. “With the significant global agricultural pressures we are seeing with mass fertilizer shortages, unprecedented climate change impact, and the urban sprawl limiting available farmlands, we believe we are in the perfect place to positively help address some of the key global food supply issues.” The Agrarius product works by activating the plants’ “defense mechanisms” at the cellular level, without the actual stress factor. The intended effect of Agrarius is that treated plants grow deeper roots and open up their foliage to optimize the effect of photosynthesis, thus increasing growth hormones, plant efficiency for water use and nutrients, decreasing the requirement of fertilizer where used, and increasing overall resistance to diseases and stressed climate conditions. Agrarius technology enables direct plant communication by mimicking naturally occurring organic molecules that correspond to various plant survival instincts, which improves the natural defense mechanisms of the plant to overcome environmental stresses. Agrarius works by sending signals that a plant understands and propagates through its roots and mycelial networks, allowing nearby plants to benefit from the signals naturally while reducing the actual amount of product that is used on a field. These signals literally send information that stimulates plant growth, subsequently increasing yields, volatility resistance, and growth speeds. By virtue of its arrangement, MVMD is an authorized reseller of Agrarius products and has commenced business development activity with large scale farming operations to induce trial activity on crops that would demonstrate the benefit to improving crop yields and the corresponding reduction in fertilizer usage where used in the specific farming operation. Additionally, the Company is working through a strategy of targeting large food supply businesses where significant purchasing power of agricultural products exists. The Company anticipates revenue from Agrarius sales activity in the 2023 calendar year related to the crop trialing cycle, whereby farming organizations would personally validate the anticipated positive impact on their crop yields and/or fertilizer reduction after it has been trialed on their farm. Revenue and the related ramp-up of sales growth in many cases is anticipated to take one full crop cycle. The Company currently facilitates Agrarius product information and product trialing and order flow through its wholly owned and developed website IncreaseCropYields.com, including translation for Spanish and Portuguese languages. The website presents product benefits, enables clients to calculate crop-specific ROI and facilitates product trialing and purchase processes. Husbandry Animals / Aquatic Species As previously disclosed, the Company has applied its Quicksol™ technology to the drug ivermectin and believes a more solubilized format versus current in-market products would have novel applications across the broad husbandry animal and aquatic species marketplace. The Company’s overall husbandry and aquatic species strategy was to develop its scientific assets with a view to licensing to third parties. Subject to final legal review and the Company’s execution of the final licensing agreement, MVMD has finalized the framework negotiations with a third party for licensing of its Soluvec™ 1% product to pursue sales in the husbandry and aquatic species marketplace inside Bangladesh. Related to the framework agreement and necessary government approvals, the pharmacokinetic trials conducted inside Bangladesh across husbandry and aquatic species categories have been completed by a third-party Contract Research Organization (CRO) and MVMD believes the results of these trials will positively support the value proposition necessary to secure necessary government approvals to commercialize inside Bangladesh in the 2023 calendar year. Management believes that commercialization of Soluvec™ 1% inside Bangladesh by the licensee will commence in the first half of the 2023 calendar year, provided the Company’s final legal review and execution of the final licensing agreement is complete. Currently, the Company is also in negotiations with a third party for licensing of its Soluvec™ 1% product worldwide (excluding Bangladesh) to further develop, produce, distribute and sell Soluvec™ 1%, or products embodying the Soluvec™ 1% technology, in the husbandry and aquatic species marketplace. The licensee would also service the production and supply of product to support the Bangladesh license agreement described above. Management believes that this is in line with its manufacturing approach to nutraceuticals, to engage with a limited number of licensees that will be able to produce/commercialize products embodying the Company’s technology, with the aim of allowing for greater protection of MVMD’s intellectual property as well as greater ease in managing licensees and resulting revenue streams. Red White and Bloom Brands In November 2021, the Company entered into an agreement with Red White and Bloom Brands Inc. (“RWB”), a publicly traded company that operates in the cannabis space in the United States. The agreement has been amended to be non-exclusive as RWB is evaluating its skew and product approach going forward and is uncertain at this point in time if RWB will expand their skew line to include MVMD’s technology. The original agreement established the terms upon which the Company’s Quicksome™ technology and novel solubilization techniques could be applied by RWB to various product applications in the space that they operate in. The Company has no immediate control of the decisions made by RWB that would bring any products with MVMD’s technology to market and is not actively pursuing any product applications in the cannabis space at this time. The decision and agreement to change the arrangement to a non-exclusive would allow MVMD to benefit from the arrangement in the future but not limit MVMD's ability to benefit from a similar arrangement with third parties. Research and Development In line with the commercialization phase described above, MVMD is shifting to a more traditional use of capital aligned to revenue growth activities. The Company will continue to assess the ability, viability, and desire to continue to develop its other projects and pre-clinical R&D work, however R&D expenditures are anticipated to be more narrowly focused on business expansion within the above three commercialization focus areas of the business, namely (1) Nutraceuticals, (2) Agricultural, and (3) Husbandry Animals. ABOUT MOUNTAIN VALLEY MD HOLDINGS INC. Mountain Valley MD is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations: patented Quicksome™ oral formulation and delivery technologies,patented Quicksol™ solubility formulation technologylicensed product reseller of Agrarius™, a novel agricultural plant signalling technology Consistent with its vision towards “More Life”, MVMD applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, MVMD’s work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage. MVMD’s patented Quicksome™ technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy. MVMD’s patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally. MVMD’s licensed Agrairus™ agricultural plant signalling technology that could be capable of application to agricultural crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change. For more Company information and contact details, visit www.MVMD.com.SOURCE: Mountain Valley MD Holdings Inc. www.MVMD.com CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company. The Company is making forward-looking statements, including but not limited to: the transition from an R&D phase to a commercialization phase of the Company’s business; the three (3) business areas of focus selected for the commercialization phase currently; the impact of the foregoing, including that these areas will best provide viable revenue streams for long-term company health and shareholder value; the ability and timing with respect to the generation of revenues; the commercialization phase being a validation of the Company’s progress; the use of a third party—lead production partner for its nutraceuticals business, the involvement of third parties and the direct agreements of such third parties with the Company, and the result of the approach being the protection of MVMD’s intellectual property, the ability to scale production, the positive impact on product quality, and the streamlining of the audit process for royalty agreements; the Company’s business development plans and goals to secure additional nutraceutical partnerships in the 2023 fiscal year; the production of consumer goods by Circadian embodying MVMD’s technology under its Eons brand, and the location and timing of such production and sales; the licensing and distribution by MVMD of Agrarius product and the relationship between such parties, and all matters related thereto, including but not limited to timing and business development efforts and details; the anticipated timing of revenues arising from Agrarius and the connection to the crop trialing cycle; the license arrangement between the Company and a third party with respect to its Quicksol™ technology in Bangladesh and all matters related thereto, including but not limited to the anticipating timing of commercialization; the anticipated arrangement with a third party regarding the development, production distribution and sale of its Soluvec™ product worldwide (excluding Bangladesh), and related matters, including but not limited to the ability of such third party to support the agreement with the third party in Bangladesh, and the impact of such an agreement, including it resulting in greater protection of MVMD”s intellectual property and greater easy in managing licensees and resulting revenue streams; MVMD”s agreement and future arrangement with RWB and the impact on MVMD of the amendment to a non-exclusive arrangement; the continued assessment of the Company’s ability, viability and desire to continue to develop its other projects and pre-clinical R&D work; and the focus of expenditures on the three (3) selected areas of business. The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation. Neither the CSE nor OTC has reviewed or approved the contents of this press release.